Market Summary | Major Indices | Market Movers | Market Sectors | Mutual Funds | A-Z Stock Listings
ETF Screener | World Markets | Currencies | CEO Wealthmeter | Oil / Energy | Metals
Treasury Rates | Calculators | My Watchlist | My Portfolio
         Symbol Lookup
THERAVANCE Add to My Watchlist (NSDQ: THRX) 
Detailed Quote
News
Chart
SEC Filings
Profile
Historical
Options
     Theravance 10.00 -0.21 (-2.06%) 49,121
901 Gateway Boulevard
South San Francisco, CA 94080 US
(650) 808-6000
(650) 827-8690 fax
www.theravance.com
CEO Rick E. Winningham
Auditor Ernst & Young LLP
Exchange Traded NQ
ISIN Number US88338T1043
CIK Number 1080014
NAICS Code 325412
Business Summary
A biopharmaceutical company with a pipeline of internally discovered product candidates.
Number of Employees 191
Share Fundamentals
Market Cap 539.98M
Shares Outstanding 54.16M
Float 50.75M
Short Interest 6.79M
Financial Strength
Revenue (TTM) $26,499,000
Earnings (TTM) -$79,017,000
Quick Ratio 3.9:1
Current Ratio 4.1:1
Total Debt/Equity 0:1
Profitability
Gross Margin N/A
EBITDA Margin N/A
Profit Margin N/A
Powered By: FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes.
All other data is delayed at least 20 minutes.
By accessing this page, you agree to the following terms and conditions.
Stock Updates provided by MarketMinute.com
Stock Analysis provided by SocialPicks Conference calls info supplied by OpenCompany
Fundamental data supplied by Mergent, Inc.
Stock quote data supplied by Telekurs